Cullinan Oncology, Inc. is a biopharmaceutical company dedicated to creating new standards of care for patients with cancer. The company innovates without borders to find the most promising clinic-ready cancer therapies, whether from its own discovery efforts or through exceptional engagement with its academic and industry partners. Cullinan Oncology is anchored in a deep understanding of immuno-oncology and translational cancer medicine. The company leverages its scientific excellence in small molecules and biologics to create differentiated ideas, identify unique targets, and select the optimal modality to develop transformative therapeutics across cancer indications. Powered by its novel research model, Cullinan Oncology pushes conventional boundaries from candidate selection to cancer therapeutic, applying rigorous early experimentation to fast-track only the most promising assets to the clinic and ultimately commercialization. As a result, Cullinan Oncology's diversified pipeline is strategically built with assets that activate the immune system or inhibit key oncogenic drivers across a wide range of modalities, each with the potential to be the best or first in their class.